Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
Conclusion: A lower incidence of bone-related safety events was observed in patients treated with exemestane. (Source: Breast Care)
Source: Breast Care - February 18, 2022 Category: Cancer & Oncology Source Type: research
Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Non-Steroidal Aromatase Inhibitors in Post-Menopausal Women with Breast Cancer: A Network Meta-Analysis
Conclusion: Lower incidence of bone-related safety events in patients treated with exemestane was observed. Further head-on studies are confirmation. (Source: Breast Care)
Source: Breast Care - February 18, 2022 Category: Cancer & Oncology Source Type: research
What Has Changed in Patients Aged 65 and Over Diagnosed with Breast Cancer during the Covid-19 Pandemic: A Single-Center Experience
Conclusion
The survey showed significant changes in breast cancer diagnosis and treatment protocols for patients diagnosed at ≥65 years old during the COVID-19 pandemic. Postponing screening and delaying treatment leads to more advanced breast cancer stages in elderly patients. (Source: Breast Care)
Source: Breast Care - February 18, 2022 Category: Cancer & Oncology Source Type: research
What Has Changed in Patients Age 65 and Over Diagnosed with Breast Cancer during the Covid-19 Pandemic: A Single-Center Experience
Conclusion
The survey showed significant changes in breast cancer diagnosis and treatment protocols for patients diagnosed at ≥65 years old during the COVID-19 pandemic. Postponing screening and delaying treatment leads to more advanced breast cancer stages in elderly patients. (Source: Breast Care)
Source: Breast Care - February 18, 2022 Category: Cancer & Oncology Source Type: research
PharmaNews
Breast Care 2022;17:117 –120 (Source: Breast Care)
Source: Breast Care - February 17, 2022 Category: Cancer & Oncology Source Type: research
First-in-Class-Therapie mit Sacituzumab Govitecan
Breast Care 2022;17:114 –116 (Source: Breast Care)
Source: Breast Care - February 17, 2022 Category: Cancer & Oncology Source Type: research
Breast Augmentation with Autologous Fat Grafting Immediately after Removal of Polyacrylamide Hydrogel (PAAG) and Fibrotic Capsule in 162 Patients
In this study we investigated the feasibility and efficacy of immediate breast augmentation with autologous fat grafting after removal of polyacrylamide hydrogel(PAAG) and fibrotic capsule.
Methods A retrospective study was conducted on 162 female patients who underwent removal of
breast filler polyacrylamide hydrogel(PAAG) and the fibrotic capsule which produced after injection of PAAG via areola Omega-shaped incision. Then autol ogous fat grafting was immediately performed evenly and radially around the areola via the same incision into different layers (subcutaneous,submammary tissue,pectoralis major intramuscular a...
Source: Breast Care - February 15, 2022 Category: Cancer & Oncology Source Type: research
The Role of C-Reactive Protein as a Prognostic Biomarker in Patients with Early Breast Cancer Treated with Neoadjuvant Chemotherapy
Conclusion: CRP at baseline is not predictive for pCR in EBC after NACT in our patient dataset. However, an association of parameters of long-term prognosis with CRP could be demonstrated. Although the correlations of higher CRP levels at baseline and shorter OS, DFS, LRFS, and DDFS were not significant, a strong trend could be detected that was reproduced in the analysis of different groups of CRP levels and the probability of breast cancer mortality. Higher CRP levels are indicating a worse prognosis in EBC after NACT in this retrospective analysis. These results justify further investigation of CRP not as a predictive p...
Source: Breast Care - February 15, 2022 Category: Cancer & Oncology Source Type: research
The Role of C-Reactive Protein (CRP) as a Prognostic Biomarker in Patients with Early Breast Cancer (EBC) Treated with Neoadjuvant Chemotherapy (NACT)
Background: C-reactive protein (CRP) is an acute phase reactant influenced by inflammation and tissue damage. Elevated CRP levels have been associated with poor outcome of various cancers including breast cancer. However, evidence regarding a potential impact of CRP levels on outcome of neoadjuvant chemotherapy (NACT) in patients with early breast cancer (EBC) is insufficient.
Methods: Patients who had received NACT for EBC and had available data regarding CRP levels before therapy, pathologic complete remission (pCR) and follow-up were included. The association between CRP at baseline and outcome parameters was analyzed....
Source: Breast Care - February 15, 2022 Category: Cancer & Oncology Source Type: research
Evaluation of the Effect of Axillary Radiotherapy Dose and the Development of Lymphedema in Breast Cancer Patients
Purpose:
The present study is aiming to correlate between different radiotherapy techniques, fractionations and doses received by each axillary LN level and axillary vessels with the development of breast cancer related lymphedema (BCRL).
Methods and materials:
We retrospectively studied 181 female breast cancer patients who were diagnosed and treated by radiation therapy during the period from January 2012- December 2017. The radiotherapy treatment plans were recalled from the archives. The axillary LN levels I, II, III, supraclavicular LN were contoured as well as axillary vessels. New dose volume histograms (DVHs) w...
Source: Breast Care - January 28, 2022 Category: Cancer & Oncology Source Type: research
Clinical Outcomes in Breast Cancer Patients with HER2-Positive, Node-Negative Tumors ( ≤3 cm)
(Source: Breast Care)
Source: Breast Care - January 27, 2022 Category: Cancer & Oncology Source Type: research
Clinical Outcomes in Breast Cancer Patients with HER2-Positive, Node-Negative Tumors ( ≤ 3 cm)
Conclusions
Patients with HER2-positive, node-negative tumors ≤ 3 cm who received trast uzumab and chemotherapy had a favorable 5-year-D-DFS (96.3%). Among them, those with a tumor 1 cm or less in size had better outcomes. (Source: Breast Care)
Source: Breast Care - January 27, 2022 Category: Cancer & Oncology Source Type: research
ABC6 Consensus: Assessment by a Group of German Experts
Background: The first ‘International Consensus Conference for Advanced Breast Cancer’ (ABC1) took place ten years ago in November 2011. The rationale was - and still is - to standardize treatment of advanced breast cancer (ABC) based on the available evidence and to ensure that world-wide all breast cancer patients r eceive adequate treatment and access to new therapies.
Rationale for the manuscript: The 6th International Consensus Confer-ence for ABC (ABC6) took place from November 4th to 6th, 2021 and was the first in a purely online format, due to the COVID-19 pandemic. In the present manuscript, a working g roup o...
Source: Breast Care - January 20, 2022 Category: Cancer & Oncology Source Type: research
Risk and Survival of Third Primary Cancers in a Population-Based Cohort of Breast Cancer Patients
Conclusion: The most common TPC sites were digestive, breast and female genital organs, with a 15-year cumulative incidence of 0.69% among FPCs. TPCs had a worse long-term survival compared to patients with an SPC only. (Source: Breast Care)
Source: Breast Care - January 19, 2022 Category: Cancer & Oncology Source Type: research
Staging for Breast Cancer: A Nationwide Survey about Adherence to Guidelines in German Breast Centers
Introduction:
The risk for metastasis at primary diagnosis of breast cancer is about 4%. The German guidelines give clear indications for when, whom and how to stage breast cancer patients. Ideally, this should be done via CAT scan of the thorax and abdomen and an additional bone scan. But daily practice shows that the way health care providers handle staging recommendations can vary. To objectify adherence to guidelines we started a nation-wide survey.
Methods:
Between July and September 2020 we sent out a survey via email to all certified and non certified breast centers and in addition to all Departments of Obstetric...
Source: Breast Care - January 14, 2022 Category: Cancer & Oncology Source Type: research
